No Data
No Data
Roth MKM Maintains Cingulate(CING.US) With Buy Rating, Cuts Target Price to $12
"Buy Rating for Cingulate Inc.: Promising Phase 3 Data and Strong Financial Outlook"
Maxim Group Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $8
Cingulate Inc's Promising Market Positioning and Accelerated Path to Market Entry for CTx-1301
Cingulate Inc Completes Key FDA Study for ADHD Drug
Express News | Cingulate Inc: Submission of New Drug Application Targeted for Mid 2025